Kimberly Blackwell - Feb 1, 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Executive Officer, Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Stock symbol
ZNTL
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/1/2023, 06:08 PM
Previous filing
Jun 16, 2022
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +245K +4896% $0.00 250K Feb 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +355K $0.00 355K Feb 1, 2023 Common Stock 355K $23.65 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.